Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 21 of 30
PK/PD Comparison of Guanfacine ER and IR
NCT01904526
iPad Application to Treat Prosodic Deficits in Students With Communication Disorders
NCT01917864
Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence
NCT01847469
Detecting Post-Operative Respiratory Depression in Children
NCT01843933
Attention Training for Opioid-maintained Cocaine Users
NCT01870882
Brain Ketone Metabolism in Type 1 Diabetes
NCT02471040
Breast Cancer Molecular Analysis Protocol
NCT01855503
Naltrexone for Antipsychotic-Induced Weight Gain
NCT01866098
Ultrasound Biofeedback for Speech Sound Disorders
NCT01905449
Linking Former Inmates to Primary Care
NCT01863290
Characterizing Clinical and Pharmacological Neuroimaging Biomarkers
NCT03842800
Survey of Smokers Treated in the Emergency Department (ED) on Ownership and Usage of Cell Phones
NCT01820533
Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone
NCT01869647
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
NCT01781026
Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
NCT01877187
The Momba Mobile Application-based Community
NCT01816945
Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients
NCT03402256
Patient Navigation for Medicaid Frequent ED Users
NCT01797068
Interactive Effects of IV Ethanol and IV Nicotine
NCT01814410
Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?
NCT01730846
Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors
NCT02112149
Study of Stress Hyperglycemia as an Indicator of Diabetes Mellitus
NCT02068989
Virtual Reality Social Cognition Training for Adults With Autism Spectrum Disorders
NCT02139514
Formative Research for an HIV Videogame for Young Black Women
NCT02685410
Integrated Stepped Care for Unhealthy Alcohol Use in HIV
NCT01410123
Second Young Adult Naturalistic Alcohol Study
NCT01780805
Effect of the InsuPatch on Automated Closed-loop Glucose Control in Type 1 Diabetes
NCT01787318
An Interactive Game for HIV Prevention in Early Adolescents
NCT01666496
A Comparison of the Blom Low Profile Voice Inner Cannula and the Passy-Muir One-Way Tracheotomy Tube Speaking Valve on Voice Production, Speech Intelligibility, and Biomechanical Swallowing Behavior
NCT01784224
SILVER-AMI: Outcomes in Older Persons With Heart Attacks
NCT01755052
A Comparative Study of Occlusive Heat Patch in the Treatment of Warts
NCT01746056
Cannabinoids and Cerebellar-Motor Functioning
NCT01853020
Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers
NCT02348385
A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment
NCT01802515
Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain
NCT02221648
Web-based CBT4CBT for Alcohol
NCT01615497
Impulsivity and Stimulant Administration
NCT01978431
On-line Treatment for Conduct Problems
NCT01822392
Open-Trial of EPI-743 for Adults With Tourette Syndrome
NCT01719523
Neurofeedback for Tourette Syndrome
NCT01702077
Barriers to Use of Remote Monitoring in Patients With Implantable Cardioverter Defibrillators
NCT02361333
Brief Web-Based Alcohol Reduction Intervention for Undergraduates
NCT01694082
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
NCT01742793
Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction
NCT01978457
Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal
NCT01618656
Performance-based Reinforcement to Enhance Cognitive Remediation Therapy
NCT01633138
Handheld Technology for Speech Development in Students With Autism
NCT01780090
Varenicline Treatment of Alcohol Dependence in Smokers
NCT01553136
Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder
NCT01691066
The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue
NCT02038595
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.